Nykode Therapeutics Presents Additional Immunogenicity Data from VB-C-03 Trial at the 2026 American Association for Cancer Research (AACR) Annual Meeting

20 Apr 2026 12:00 CEST

• Nykode presents additional immunogenicity data from the VB-C-03 trial at AACR
showing immunogenicity in 100% of the 10 evaluable patients in the 6 and 9 mg
dose groups.

Oslo, Norway, April 20, 2026 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced the poster presentation of
additional immunogenicity data from the VB-C-03 clinical trial at the 2026
American Association for Cancer Research (AACR) Annual Meeting.

The data build on results initially presented at the 10th International Congress
on Innovative Approaches in Head & Neck Oncology (ICHNO) in March 2026, which
demonstrated a confirmed objective response rate of 38.5% and strong
immunogenicity signals. The current results support an even more robust
immunogenicity, with now 11 evaluable patients, where all 10 patients (100%) in
the 6 and 9 mg dose groups showed HPV16-specific vaccine-induced immune
responses. The responses were both rapid and durable, with a demonstrated
persistence into the last analyzed timepoint at the completed end-of-treatment.

"The consistency and strength of the T-cell responses we are observing across
patients underscore that abi-suva has the makings of a best-in-class vaccine for
HPV16-positive cancers. For patients with recurrent or metastatic head and neck
cancer, where current treatments offer a response rate of only around 19%, a
therapy that can generate this quality of immune response alongside meaningful
clinical activity could represent a real step forward. We enter the Abili-T
trial with a well-defined dose, a strong immune response profile, and a
competitive data package that sets abi-suva apart from other approaches in this
indication and we are deeply motivated by the opportunity to make a difference
for these patients,” said Agnete Fredriksen, CSO and Co-founder of Nykode
Therapeutics

The poster will be available after the session at the Company’s Webpage:
https://nykode.com/research-and-development/scientific-papers-and-presentations/

 
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode’s modular immunotherapy
technology specifically targets antigens to antigen presenting cells (APC),
which have been shown to induce a broad, strong and long-lasting antigen
specific immune response in cancer, which correlates with clinical responses.

Nykode’s lead product candidates are abi-suva, a therapeutic immunotherapy for
the treatment of HPV16 induced malignancies which demonstrated favorable safety
and efficacy results from its Phase 2 trial for the treatment of late-line r/m
cervical cancer. Abi-suva is currently being further developed in first line
head and neck cancer with the randomized Abili-T trial with interim results
within 2027. VB10.NEO, an individualized cancer neoantigen immunotherapy, has
been investigated in two trials with more than 10 different indications.

Nykode is also utilizing its APC-targeted technology to create an immune
tolerance platform for the potential use in autoimmune disorders, organ
transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

More information:
Access the news on Oslo Bors NewsWeb site

670952_260420 - AACR press release_FINAL.pdf